Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 18/20 | 0.85 |
| ▸ | BCR | P11274 | 17/20 | 0.85 |
| ▸ | PDGFRA | P16234 | 10/20 | 0.85 |
| ▸ | PDGFRB | P09619 | 7/20 | 0.85 |
| ▸ | SRC | P12931 | 6/20 | 0.85 |
| ▸ | SYK | P43405 | 2/20 | 0.85 |
| ▸ | KIT | P10721 | 7/20 | 0.69 |
| ▸ | ABL2 | P42684 | 2/20 | 0.69 |
| ▸ | PLK4 | O00444 | 1/20 | 0.69 |
| ▸ | DDX3X | O00571 | 1/20 | 0.69 |
| ▸ | GAK | O14976 | 1/20 | 0.69 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.69 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.69 |
| ▸ | CA12 | O43570 | 1/20 | 0.69 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.69 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.69 |
| ▸ | EGFR | P00533 | 1/20 | 0.69 |
| ▸ | CA1 | P00915 | 1/20 | 0.69 |
| ▸ | CA2 | P00918 | 1/20 | 0.69 |
| ▸ | LMNA | P02545 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9485 | 0.92 | ABL1 (1.00) | ABL1BCRPDGFRAPDGFRBSRC | |
| SCHEMBL3858318 | 0.92 | ABL1 (0.84) | ABL1BCRPDGFRAPDGFRBSRC | |
| SCHEMBL13038805 | 0.90 | ABL1 (0.82) | ABL1BCRPDGFRAPDGFRBSRC | |
| SCHEMBL8261009 | 0.89 | ABL1 (0.94) | ABL1BCRPDGFRAPDGFRBSRC | |
| SCHEMBL3866664 | 0.89 | ABL1 (0.94) | ABL1BCRPDGFRAPDGFRBSRC | |
| SCHEMBL3864378 | 0.88 | ABL1 (0.81) | ABL1BCRPDGFRAPDGFRBSRC | |
| SCHEMBL3867814 | 0.86 | ABL1 (0.88) | ABL1BCRPDGFRAPDGFRBSRC | |
| SCHEMBL3869324 | 0.85 | ABL1 (0.78) | ABL1BCRPDGFRAPDGFRBSRC | |
| SCHEMBL2992321 | 0.84 | ABL1 (0.73) | ABL1BCRPDGFRAPDGFRBSRC | |
| SCHEMBL31553098 | 0.84 | ABL1 (0.94) | ABL1BCRPDGFRAPDGFRBSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230302144-A1 | Porphyrin Compounds and Compositions Useful for Treating Cancer | ONCOSELECT THERAPEUTICS, LLC (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230302144-A1 | Porphyrin Compounds and Compositions Useful for Treating Cancer | ONCOSELECT THERAPEUTICS, LLC (US) | 2023-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230302144-A1 | Porphyrin Compounds and Compositions Useful for Treating Cancer | KIT, HCCS, PPIF | ABL1 692/4885BCR 277/4885PDGFRA 2688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.